AKT1 and cancer: In conclusion, our results unveil the anti-cancer mechanism of action of the second-generation imiqualine EAPB02303 in C. elegans. EAPB02303 displayed IIS- and Ras-inhibitory activity, thus holding promising therapeutic expectations in malignant tumors with deregulated PI3K-Akt signaling and/or oncogenic Ras.